Showing posts with label skin cancer. Show all posts
Showing posts with label skin cancer. Show all posts

Monday, 12 October 2020

Cutaneous areas at risk for non-melanoma skin cancer

The National Comprehensive Cancer Network (NCCN) guidelines (squamous cell carcinoma [1] and basal cell carcinoma [2]) classify high-risk lesions by size and location, as follows:

  • 2 cm or more in diameter in low-risk locations (areas L):
    • trunk and extremities, but not including the pretibia, hands, feet, ankles, and nail units.
  • 1 cm or more in diameter in moderate-risk locations (area M):
    • cheeks, forehead, scalp, neck, and pretibia.
  • The area H, independent of size:
    • The "mask area" of the face:
      • Central face, eyelids, eyebrows, periorbital, nose, lips (cutaneous and vermillion), chin, mandible, preauricular and postauricular skin/sulci, temple, and ear.
    • Genitalia, hands, and feet.

Head and neck H and M areas:
Source: [3]

Source: [4]

Body H, M, and L areas [3]:

Bibliographic references:
[1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Squamous Cell Skin Cancer, Version 2.2020 - July 14, 2020 [Internet]. Nccn.org. 2020 [cited 12 October 2020]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
[2] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Basal Cell Skin Cancer, Version 1.2020 - October 24, 2020 [Internet]. Nccn.org. 2020 [cited 12 October 2020]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf.
[3] Blechman et al. Application of Mohs micrographic surgery appropriate-use criteria to skin cancers at a university health system. J Am Acad Dermatol. 2014 Jul;71(1):29-35. Available at: https://doi.org/10.1016/j.jaad.2014.02.025.
[4] Dębski T, et al. Basal cell carcinoma. Current views (Part II). Diagnostics and treatment. Borgis - Postępy Nauk Medycznych 2009;9:706-13 [cited 12 October 2020]. Available at: http://ksiaznica.home.pl/pnm/spnm.php?ktory=518.

Wednesday, 1 January 2020

PD-1 checkpoint inhibitors

A PD-1 (programmed cell death protein 1) inhibitor fairy tale:


How do tumors use PD-1 to cause T-cell exhaustion? Learn how overexpression of PD-1 receptors on T cells may lead to T-cell exhaustion:

Saturday, 23 November 2019

Reirradiation of skin tumors


Slides from Anita O'Donovan, Assistant Professor, Discipline of Radiation Therapy, Trinity College, Dublin, Ireland.
In ESTRO course on Multidisciplinary Management of Non-Melanoma Skin Cancer, Brussels, Belgium, November 9, 2019.


Link to Virginia M. (2016). Reirradiation of Skin Tumors. M J Canc. 1(1): 003: https://www.mathewsopenaccess.com/scholarly-articles/reirradiation-of-skin-tumors.pdf.